Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
TScan Therapeutics, Inc. (TCRX)
|
Add to portfolio |
|
|
|
| Price: |
$4.68
| | Metrics |
| OS: |
47.8
|
M
| |
|
|
| Market cap: |
$224
|
M
| |
|
|
|
Net cash:
|
$209
|
M
| |
$4.37
|
per share
|
|
EV:
|
$14.9
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($99.3)
|
M
| |
|
|
| EPS |
($1.44)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 13.5 | 59.8 | 10.1 | 45.0 | 1.1 | 9.4 |
| Revenue growth | 33.5% | 33.1% | 834.7% | | -88.5% | |
| Cost of goods sold | 0.0 | 80.2 | 0.0 | 58.8 | 0.0 | 14.2 |
| Gross profit | 13.5 | -20.4 | 10.1 | -13.8 | 1.1 | -4.8 |
| Gross margin | 100.0% | -34.0% | 100.0% | -30.8% | 100.0% | -50.5% |
| Research and development | 59.8 | | 45.0 | | 20.6 | |
| General and administrative | 20.4 | 20.4 | 13.8 | 13.8 | 6.7 | 4.8 |
| EBIT | -66.6 | -66.6 | -48.6 | -48.6 | -26.2 | -14.2 |
| EBIT margin | -492.3% | -111.4% | -479.6% | -108.2% | -2417.8% | -150.5% |
| Pre-tax income | -66.2 | -66.2 | -48.6 | -48.6 | -26.1 | -13.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -66.2 | -66.2 | -48.6 | -48.6 | -26.1 | -13.7 |
| Net margin | -489.3% | -110.7% | -479.5% | -108.2% | -2408.0% | -144.7% |
| |
| Diluted EPS | ($2.75) | ($2.75) | ($4.17) | ($4.17) | ($28.52) | ($35.47) |
| Shares outstanding (diluted) | 24.0 | 24.0 | 11.7 | 11.7 | 0.9 | 0.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|